Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: A retrospective analysis

Nutrition and Cancer

Volumn 67, Issue 3, 2015, Pages 424-430

  Wesa, Kathleen M ^a   Segal, Neil H ^a   Cronin, Angel M ^b   Sjoberg, Daniel D ^a   Jacobs, Gria N ^a   Coleton, Marci I ^a   Fleisher, Martin ^a   Dnistrian, Ann M ^a   Saltz, Leonard B ^a   Cassileth, Barrie R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; CARCINOEMBRYONIC ANTIGEN; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OVERALL SURVIVAL; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; AGED; ANALOGS AND DERIVATIVES; BLOOD; BODY MASS; COLORECTAL TUMOR; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL;

AGED; BODY MASS INDEX; COLORECTAL NEOPLASMS; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 84926518958     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2015.998838     Document Type: Article

References (43)

1. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, et al.: Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167, 1159-1165, 2007.
2. Holick MF: The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol Aspects Med 29, 361-368, 2008.
3. Lee JH, O'Keefe JH, Bell D, Hensrud DD, and Holick MF: Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 52, 1949-1956, 2008.
4. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, et al.: Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96, 1911-1930, 2011.
5. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, et al.: The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96, 53-58, 2011.
6. Feldman D, Krishnan AV, Swami S, Giovannucci E, and Feldman BJ: The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14, 342-357, 2014.
7. Sieg J, Sieg A, Dreyhaupt J, and Schmidt-Gayk H: Insufficient vitamin D supply as a possible co-factor in colorectal carcinogenesis. Anticancer Res 26, 2729-2733, 2006.
8. Giovannucci E, Liu Y, and Willett WC: Cancer incidence and mortality and vitamin D in black and white male health professionals. Cancer Epidemiol Biomarkers Prev 15, 2467-2472, 2006.
9. Giovannucci E: Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 19, 84-88, 2009.
10. Giovannucci E: Epidemiology of vitamin D and colorectal cancer: casual or causal link? J Steroid Biochem Mol Biol 121, 349-354, 2010.
11. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, et al.: Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 97, 179-194, 2005.
12. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, et al.: Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol 26, 2984-2991, 2008.
13. Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, et al.: A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 99, 1120-1129, 2007.
14. Giovannucci E: Epidemiology of vitamin D and colorectal cancer. Anticancer Agents Med Chem 13, 11-19, 2013.
15. Matusiak D, Murillo G, Carroll RE, Mehta RG, and Benya RV: Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiol Biomarkers Prev 14, 2370-2376, 2005.
16. Murtaugh MA, Sweeney C, Ma KN, Potter JD, Caan BJ, et al.: Vitamin D receptor gene polymorphisms, dietary promotion of insulin resistance, and colon and rectal cancer. Nutr Cancer 55, 35-43, 2006.
17. Slattery ML, Herrick J, Wolff RK, Caan BJ, Potter JD, et al.: CDX2 VDR polymorphism and colorectal cancer. Cancer Epidemiol Biomarkers Prev 16, 2752-2755, 2007.
18. Kure S, Nosho K, Baba Y, Irahara N, Shima K, et al.: Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 18, 2765-2772, 2009.
19. Touvier M, Chan DS, Lau R, Aune D, Vieira R, et al.: Meta-Analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 20, 1003-1016, 2011.
20. Muindi JR, Adjei AA, Wu ZR, Olson I, Huang H, et al.: Serum vitamin D metabolites in colorectal cancer patients receiving cholecalciferol supplementation: correlation with polymorphisms in the vitamin D genes. Horm Cancer 4, 242-250, 2013.
21. Tangpricha V, Spina C, Yao M, Chen TC, Wolfe MM, et al.: Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr 135, 2350-2354, 2005.
22. Holt PR, Arber N, Halmos B, Forde K, Kissileff H, et al.: Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 11, 113-119, 2002.
23. Krishnan AV and Feldman D: Mechanisms of the anti-cancer and antiinflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 51, 311-336, 2011.
24. Murillo G, Matusiak D, Benya RV, and Mehta RG: Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. J Steroid Biochem Mol Biol 103, 763-767, 2007.
25. Gonzalez-Sancho JM, Larriba MJ, Ordonez-Moran P, Palmer HG, and Munoz A: Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res 26, 2669-2681, 2006.
26. Grant WB and Holick MF: Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 10, 94-111, 2005.
27. Heaney RP and Holick MF: Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res 26, 455-457, 2011.
28. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, et al.: Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 32, 210-216, 2007.
29. Goodwin PJ, Ennis M, Pritchard KI, Koo J, and Hood N: Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27, 3757-3763, 2009.
30. Rose AA, Elser C, Ennis M, and Goodwin PJ: Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and metaanalysis. Breast Cancer Res Treat 141, 331-339, 2013.
31. Peppone LJ, Rickles AS, Janelsins MC, Insalaco MR, and Skinner KA: The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol 19, 2590-2599, 2012.
32. Lee JE, Li H, Chan AT, Hollis BW, Lee IM, et al.: Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-Analysis of prospective studies. Cancer Prev Res (Phila) 4, 735-743, 2011.
33. Fakih MG, Trump DL, Johnson CS, Tian L, Muindi J, et al.: Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int J Colorectal Dis 24, 219-224, 2009.
34. Giovannucci E: Epidemiological evidence for vitamin D and colorectal cancer. J Bone Miner Res 22 (Suppl 2), V81-V85, 2007.
35. Mezawa H, Sugiura T, Watanabe M, Norizoe C, Takahashi D, et al.: Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc analysis of a prospective cohort study. BMC Cancer 10, 347, 2010.
36. Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, et al.: Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol 29, 1599-1606, 2011.
37. Arneson WL and Arneson DL: Current methods for routine clinical laboratory testing of Vitamin D levels. Lab Med 44, E38-E42, 2013.
38. Vashi PG, Lammersfeld CA, Braun DP, and Gupta D: Serum 25-hydroxyvitamin D is inversely associated with body mass index in cancer. Nutr J 10, 51, 2011.
39. Fiscella K, Winters P, Tancredi D, Hendren S, and Franks P: Racial disparity in death from colorectal cancer: does vitamin D deficiency contribute? Cancer 117, 1061-1069, 2011.
40. Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, et al.: Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-Activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 1, 821-829, 2002.
41. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, et al.: Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57, 3759-3764, 1997.
42. Moffatt KA, Johannes WU, and Miller GJ: 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5, 695-703, 1999.
43. Milczarek M, Rosinska S, Psurski M, Maciejewska M, Kutner A, et al.: Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res 33, 433-444, 2013.